Therefore, early detection of T790M mutation during the first-line therapy and changing of the drug to 3rd generation EGFR TKIs included osimertinib are extremely important in disease management for NSCLC patients with EGFR mutations [9]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.